Mesenchymal stem cells for targeted cancer therapy
OwnerAstra Chang, Jan Noltainventors
Life of this patent
Estimating the term…
Abstract
An isolated polynucleotide comprising the element of: a promoter element that drives expression of the C—C motif ligand 5 (“a CCL5 promoter”) operatively linked to a polynucleotide encoding a fusion polypeptide comprising the Fc and hinge regions of a human IgG CD44 variant 6 (CD44v6) polypeptide is described.
Claims37
A method for one or more of:
- a. delivering a fusion polypeptide to a tumor cell expressing CD44 marker;
- and/or
- b. for inducing an immune response in a subject in need thereof;
- and/or,
- c. for inhibiting the growth of a tumor in a subject in need thereof;
- comprising contacting the tumor cell or administering to the subject with an effective amount of an isolated host cell comprising an isolated polynucleotide, wherein the polynucleotide comprises a promoter element that drives expression of the C—C motif ligand 5 (“a CCL5 promoter”) operatively linked to a polynucleotide encoding the fusion polypeptide, the fusion polypeptide comprising the Fc region of a human antibody selected from the group:
- IgG1, IG2, IgG3, IgG4, IgA1, IgA2 or IgM and a ScFv region of an anti-CD44 polypeptide, or an equivalent of each thereof.
(canceled)
(canceled)
10-11. (canceled)
13-15. (canceled)
An isolated polynucleotide, comprising, or alternatively consisting essentially of, or yet further consisting of, a promoter element that drives expression of the C—C motif ligand 5 (“a CCL5 promoter”) operatively linked to a polynucleotide encoding the fusion polypeptide, the fusion polypeptide comprising the Fc region of a human antibody selected from the group:
- IgG1, IG2, IgG3, IgG4, IgA1, IgA2 or IgM and a ScFv region of an anti-CD44 polypeptide, or an equivalent of each thereof.
(canceled)
(canceled)
26-27. (canceled)
29-31. (canceled)
(canceled)
37-40. (canceled)
44-52. (canceled)
54-56. (canceled)
Dependencies are inferred from the claim text.